Myeloma Patients Europe (MPE) attended the 65^th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.

Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains the latest findings on the KarMMa-3 trial and the impact abecma has on Quality of Life (QoL) presented at ASH 2023.

Watch the video interview here.

Dr. Moshe Gatt, Department of Haematology, Hebrew University of Jerusalem, Israel, explains the latest findings of the HBI0101 therapy for AL amyloidosis patients and its potential application in this rare disease.

Watch the video interview here.

Dr.Sæmundur Rögnvaldsson, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, explains the latest findings of the iStopMM study presented at ASH 2023.

Watch the video interview here. 

Prof. Pieter Sonneveld, Professor of Haematology and Head of the Department of Haematology at the Erasmus MC Cancer Institute and Professor of Haematology at the Erasmus University of Rotterdam, The Netherlands, presented the only late-breaking abstract on myeloma at ASH 2023. Watch the interview on the key insights on the Perseus Trial, a Phase 3 study comparing Daratumumab + VRd to VRd alone in transplant-eligible newly diagnosed myeloma patients.

Watch the video interview here.

Prof. Pieter Sonneveld, Professor of Haematology and Head of the Department of Haematology at the Erasmus MC Cancer Institute and Professor of Haematology at the Erasmus University of Rotterdam, The Netherlands, explains the main results of the EMN26 Study: iberdomide maintenance after autologous stem-cell Transplantation.

Watch the video interview here.

Carmen Gonzalez from Cancer Center Clinica Universidad de Navarra, Spain, explains how minimally invasive methods could be the key to a smoother patient experience and the latest findings of MRD measurements presented at ASH 2023.

Watch the video interview here.

Dr. Krzysztof Giannopoulos, Department of Experimental Haematooncology, Medical University of Lublin, Lublin, Poland, explains the latest findings of the ATLAS trial presented at ASH 2023.

Watch this video interview here.

Dr. Ajai Chari, Director of the Myeloma Programme and Professor of Clinical Medicine at the University of California, San Francisco, USA, explains the latest findings of the MonumenTAL 1 study results, which showcased promising results in the trial with overall response rates exceeding 71% and a manageable safety profile.

Watch this video interview here.

Prof. Monique Minnema, Internist and Haematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht, The Netherlands, explains the most important updates on AL amyloidosis presented at ASH 2023.

Watch the video interview here. 

Dr. Martin Kaiser, Haematologist at the Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom, summarised the results of the OPTIMUM/MUKnine clinical trial of ultra-risk myeloma patients.

Watch the video interview here.